Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Oldesloe – page 69

1 417 clinical trials in Bad Oldesloe, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Oldesloe at a glance
1 417
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 417 trials in Bad Oldesloe

Open in trial search

Hidradenitis

Not recruiting

A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BFB759
  • Sponsor:Bluefin Biomedicine Inc.

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Study on Estriol Vaginal Ring for Treating Vaginal Atrophy in Postmenopausal Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Estriol
  • Sponsor:SocraTec R&D Concepts in Drug Research and Development GmbH

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Sanofi Winthrop Industrie

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Arteriosclerosis+2

Not recruiting

Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Hyperlipidaemia

Not recruiting

Study on Lowering Cholesterol with Rosuvastatin or Rosuvastatin/Ezetimibe in Patients at High or Very High Risk of Cardiovascular Disease with High Cholesterol

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ezetimibe
  • Sponsor:KRKA tovarna zdravil d.d. Novo mesto

Type 1 diabetes mellitus+2

Not recruiting

Efficacy and Safety of Tirzepatide Versus Placebo in Adults with Type 1 Diabetes and Obesity or Overweight: A Phase 3 Randomized Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Vasoconstriction

Not recruiting

Evaluation of topical clascoterone versus drug combination for skin vasoconstriction in healthy volunteers

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Clascoterone
  • Sponsor:Cassiopea S.p.A.

Obesity+1

Not recruiting

A Phase 3 Study of Once‑Monthly PF‑08653944 vs Placebo for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Berobenatide
  • Sponsor:Pfizer Inc.

Cardiac amyloidosis

Not recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Oldesloe

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on anticoagulation therapy in patients with irregular heartbeat who have undergone coronary stent placement. The research evaluates new approaches to prevent blood clot formation while maintaining patient safety.

  • Atrial Fibrillation Management
  • Post-PCI Treatment Strategies
  • Bleeding Risk Assessment

These trials aim to optimize antithrombotic treatment regimens following coronary interventions.

02 Coronary Interventions

Advanced research investigating treatment strategies for patients with ST-Elevated Myocardial Infarction, comparing different approaches to antiplatelet therapy and revascularization techniques.

  • Prasugrel-based Therapy
  • OCT-guided Procedures
  • Stent Optimization

The studies focus on improving outcomes in heart attack patients through innovative imaging and medication protocols.

03 Interventional Cardiology

Comprehensive evaluation of dual antiplatelet therapy protocols and their optimization in patients undergoing coronary interventions, with special attention to timing and duration of treatment.

  • Revascularization Techniques
  • Medication Protocols
  • Patient Safety Outcomes

These studies aim to establish more effective and safer treatment strategies for cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.